Narcolepsy

In a recent survey, key factors associated with perceived support included knowing someone who had the same diagnosis of their sleep disorder, younger age, and marital status.

The neurologist and sleep disorder specialist at Allegheny Health Network discussed the challenges with preventing narcolepsy and the strategies patients can take to improve their overall prognosis. [WATCH TIME: 4 minutes]

The neurologist and sleep disorder specialist at Allegheny Health Network provided an in-depth exploration of the current advancements and future directions in narcolepsy drug development. [WATCH TIME: 3 minutes]

In a previously completed phase 1 study, the treatment resulted in significant improvements in wakefulness at doses of 1.0 mg and 2.5 mg, prompting a follow-up study.

The director of Child Neurology and Pediatric Sleep Medicine at Geisinger Janet Weis Children's Hospital talked about how the recent approval of once-nightly sodium oxybate for pediatric narcolepsy enables more effective and manageable treatment options for children and families.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Anne Marie Morse, DO, FAASM. [LISTEN TIME: 12 minutes]

The director of Child Neurology and Pediatric Sleep Medicine at Geisinger Janet Weis Children's Hospital provided her immediate reaction to the approval of a once-nightly sodium oxybate for pediatric narcolepsy. [WATCH TIME: 7 minutes]

Sodium oxybate is the only FDA-approved once-at-bedtime treatment for cataplexy or excessive daytime sleepiness in pediatric patients with narcolepsy.

In the phase 1 trial, the 2.5 mg dose of ORX750 significantly improved wakefulness, restoring normal sleep latency to 32 minutes compared to placebo.

Vibrance-2 is a double-blind, placebo-controlled trial with 80 participants, assessing three doses of ALKS 2680 over eight weeks

The double-blind, single-dose, 5-period crossover study is expected to include approximately 40 patients with narcolepsy type 1 to test 3 dose strengths of E2086.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on care of idiopathic hypersomnia.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Phil Jochelson, MD. [LISTEN TIME: 20 minutes]

The therapeutic head for Clinical Development Neuroscience at Jazz Pharmaceuticals discussed how sodium oxybate has evolved over the years and the educational aspects of cardiovascular implications patients and clinicians should be aware of. [WATCH TIME: 3 minutes]

The therapeutic head for Clinical Development Neuroscience at Jazz Pharmaceuticals provided clinical insight on a new study evaluating the effect of switching from high- to low-sodium oxybate on blood pressure. [WATCH TIME: 4 minutes]

Pitolisant is the first and only drug in the class of antagonist/reverse agonists of the histamine H3 receptor for the treatment of patients with narcolepsy.

Across both the primary and secondary end points, treatment with TAK-861 resulted in significant improvements in symptom severity among patients with narcolepsy type 1.

Ron Grunstein, MD, PhD, head of Sleep and Circadian Research at the Woolcock Institute of Medical Research, provided commentary on early, promising data regarding investigational agent ALKS 2680 in patients with narcolepsy type 1.

Alkermes embarks on the phase 2 Vibrance-1 trial to evaluate the safety and efficacy of ALKS 2680 against placebo as a once-daily treatment for narcolepsy type 1.

Alberto Ramos, MD, FAAN, director of the Sleep Disorders program at the University of Miami, provided commentary on a session chaired at AAN 2024 assessing the diagnostic criteria and treatment options of parasomnias in adults.

Experts in sleep medicine summarize the available safety data on various agents for the treatment of narcolepsy.

Drs Thorpy, Dogan, Doghramji, and Kushida review the various treatment classes for narcolepsy.

Sleep medicine experts discuss how to select the appropriate treatment for narcolepsy.

ALKS 2680, an investigational orexin 2 receptor agonist, showed promise for improving sleep latency in patients with narcolepsy type 2 and idiopathic hypersomnia in a phase 1b study.

The newly initiated phase 3 trial follows a successful phase 2 study where treatment with pitolisant resulted in greater improvement on the Epworth Sleepiness Scale for Children and Adolescents than placebo.